Compare AbbVie Inc (ABBV) vs SPDR Gold Trust (GLD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs SPDR Gold Trust — how do they compare? AbbVie Inc trades at $253.67 (market cap $449.91B), while SPDR Gold Trust trades at $375.23. The key difference: AbbVie Inc pays a 2.72% dividend while SPDR Gold Trust pays none, and AbbVie Inc is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals.
| ABBV | GLD | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $495.90 |
52-Week Low | $184.85 | $300.96 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
GLD trades at $382.13, up 1.06% with a bearish technical signal from moving averages. Recent news highlights central bank gold purchases and analyst price targets near $4,600 per ounce for physical gold. The fund shows strong annual returns of 22.27% but faces resistance near $383-$387 levels amid mixed oscillators.
Outlook remains cautiously optimistic with institutional demand supporting prices, though technical resistance and Fed policy uncertainty pose near-term risks. Long-term bullion fundamentals appear intact, but volatility may persist around key economic data releases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →
